


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A method to therapeutically treat a condition selected from the group consisting of pain, stroke, epilepsy, anxiety and depression in a subject, which method comprises administering to a subject in need of such treatment an amount of a compound of formula (1) effective to treat said condition wherein said compound of formula (1) is:



or an isolated stereoisomer thereof and/or a pharmaceutically acceptable salt thereof wherein each R^1 - R^5 is independently optionally substituted C_{1-10} alkyl (4-10C), C_{2-10} alkenyl (2-10C), C_{2-10} alkynyl (2-10C), C_{6-10} aryl (6-10C), C_{7-16} alkylaryl (7-16C) or C_{7-16} alkenylaryl (7-16C) each optionally further containing 1-4 heteroatoms selected from the group consisting of N, O, and S, (N, O or S) and wherein said optional substituents may include =O; or each of R^1 , R^2 , R^4 , and R^5 R^1 - R^5 is independently halo, NO_2 , SO, SO_2 , SO_2NH_2 , OH, ~~OH~~, SH or NH_2 , and R^3 is halo, NO_2 , SO, SO_2 , SO_2NH_2 , OH, SH, NH_2 or wherein R^3 may be keto if $n^3=1$; and

wherein two substituents on adjacent positions of the same ring may form a 3-7 membered saturated or unsaturated ring fused to said substituted ring, said fused ring itself optionally substituted and optionally containing one or more heteroatoms selected from the group consisting of N, O, and S (N, S, O); or

wherein a combination of R^1 and R^2 and/or R^4 and R^5 may form a bond or a bridge between phenyl groups A and B and/or C and D; and

wherein each n^1 , n^2 , n^3 , n^4 and n^5 is independently 0-4; and/or
wherein when n^3 is 0, then the compound of formula (1) is in the form of an isolated stereoisomer or a pharmaceutically acceptable salt thereof; or the compound of formula (1) is P49 or P50 in Figure (1) or a pharmaceutically acceptable salt thereof.

2. (Currently amended) The method of claim 1, wherein each of R^1 , R^2 , R^4 and R^5 is independently halo, or is optionally heteroatom containing and/or optionally substituted C₁₋₁₀ alkyl (1-10C), C₂₋₁₀ alkenyl (2-10C), C₆₋₁₀ aryl (6-10C), C₇₋₁₆ arylalkyl (7-16C), or C₇₋₁₆ alkenylaryl (7-16C).

3. (Withdrawn) The method of claim 1, wherein R^1 and R^2 and/or R^4 and R^5 form a bridge of 1-3 members.

4. (Withdrawn) The method of claim 1, wherein n^3 is 1 and R^3 is COOH or an alkyl ester thereof.

5. (Withdrawn) The method of claim 1, wherein all of n^1 - n^2 and n^4 - n^5 are 0.

6. (Previously presented) The method of claim 1, wherein one of n^1 - n^2 and n^4 - n^5 is 1 and the other n are 0.

7. (Withdrawn) The method of claim 1, wherein one of n^1 - n^2 and n^4 - n^5 is 2 and the other n are 0.

8. (Withdrawn) The method of claim 1, wherein one of n^1 - n^2 and n^4 - n^5 is 3 and the other n are 0.

9. (Withdrawn) The method of claim 1, which is compound P37-P50 in Figure 1 or a salt thereof.

10. (Previously presented) The method of claim 1, wherein the condition is pain.
11. (Withdrawn) The method of claim 1, wherein the condition is stroke.
12. (Withdrawn) The method of claim 1, wherein the condition is epilepsy.
13. (Withdrawn) The method of claim 1, wherein the condition is anxiety or depression.
14. (Withdrawn) The method of claim 5, wherein the condition is pain.
15. (Withdrawn) The method of claim 5, wherein the condition is stroke.
16. (Withdrawn) The method of claim 5, wherein the condition is epilepsy.
17. (Withdrawn) The method of claim 5, wherein the condition is anxiety or depression.
18. (New) The method of claim 1, wherein said optional substituents of R¹-R⁵ include =O.
19. (New) The method of claim 1, wherein n³ is 1 and R³ is keto.